Cenobamate in Real‐Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study
ABSTRACT Background Pharmacoresistance imposes a high burden on people with epilepsy (PWE). Recently authorized cenobamate (CNB) offers new hope with high efficacy reported in phase III and early real‐world studies. Here, we present data from a reasonably sized monocentric cohort, complementing the...
Saved in:
| Main Authors: | Mostafa Badr, Christoph Helmstaedter, Susanna Moskau‐Hartmann, Jan Pukropski, Juri‐Alexander Witt, Theodor Rüber, Karmele Olaciregui Dague, Tobias Baumgartner, Michael Rademacher, Rainer Surges, Randi vonWrede |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.70567 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rash and edema shortly after initial exposure to low dose cenobamate
by: Christopher Saouda, et al.
Published: (2025-09-01) -
Cenobamate reduces epileptiform activity in the ex vivo F98 rat glioma model
by: Ferdinand Forberger, et al.
Published: (2025-08-01) -
Increase of Brivaracetam serum concentration with introduction of Cenobamate
by: Lena Bender, et al.
Published: (2025-04-01) -
Cenobamate for Adjunctive Treatment in Adult and Pediatric Patients with Refractory Lennox–Gastaut Syndrome: A Retrospective Chart Review
by: Karen Keough, et al.
Published: (2025-06-01) -
A french real-world experience with cenobamate in patients with drug-resistant focal epilepsy: A retrospective observational study
by: Antoine Plaquevent, et al.
Published: (2025-09-01)